Andrew Armstrong, MD
Medical Oncology · Durham, NCNPI 1528160199
Payments from drug & device makers
Across 498 payments — averaging $17,309 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4.8M
- Bristol Myers Squibb$1M
- E.r. Squibb & Sons, L.L.C.$762K
- Astellas Pharma Global Development$383K
- Janssen Research & Development, LLC$365K
- Amgen$338K
- plus $1M from 26 others
Across 249 payments — averaging $424.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astellas Pharma Global Development$52K
- Pfizer$26K
- Novartis$14K
- Bayer$13K
What the payments were for
- Consulting fees$247,41766%
- Speaking & faculty fees$96,25226%
- Travel & lodging$27,8337%
- Food & beverage$5,4521%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 111 | $4,754,244 |
| Bristol Myers Squibb | 8 | $1,015,591 |
| E.r. Squibb & Sons, L.L.C. | 39 | $762,436 |
| Astellas Pharma Global Development | 41 | $382,611 |
| Janssen Research & Development, LLC | 9 | $364,823 |
| Amgen | 15 | $337,504 |
| AstraZeneca | 99 | $280,062 |
| Gilead | 5 | $249,457 |
| Pfizer | 38 | $154,854 |
| F. Hoffmann-la Roche AG | 6 | $99,795 |
| Bayer | 34 | $56,890 |
| Astrazeneca UK Limited | 21 | $49,284 |
| Beigene, Ltd. | 11 | $34,555 |
| Astellas Pharma Europe Ltd | 13 | $33,984 |
| Astellas Pharma US Inc | 4 | $11,810 |
| Novartis | 6 | $6,130 |
| Eisai Inc. | 3 | $3,530 |
| Janssen Global Services, LLC | 4 | $3,488 |
| Advanced Accelerator Applications | 1 | $3,144 |
| Exelixis Inc. | 3 | $2,837 |
| Dendreon Pharmaceuticals LLC | 5 | $2,375 |
| Sumitomo Pharma America, Inc. | 3 | $2,342 |
| Clovis Oncology, Inc. | 1 | $2,265 |
| Cipla USA Inc. | 1 | $2,000 |
| Telix Pharmaceuticals | 1 | $1,500 |
| Menarini Silicon Biosystems, Inc. | 3 | $816 |
| Myovant Sciences Inc. | 1 | $750 |
| Sanofi | 5 | $438 |
| Biosense Webster, Inc. | 3 | $167 |
| Progenics Pharmaceuticals, Inc. | 1 | $154 |
| Roche Products Limited | 1 | $53 |
| Janssen Scientific Affairs, LLC | 2 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XTANDI$73,398
- TALZENNA$47,201
- LYNPARZA$42,225
- Xofigo$26,531
- OPDIVO$6,540
- PLUVICTO$5,950
- Nubeqa$4,487
- ORGOVYX$3,517
- LENVIMA$3,500
- Erleada$3,476
- ILLUCCIX$3,000
- Cabometyx$2,837
- PROVENGE$2,298
- Rubraca$2,265
- ENZALUTAMIDE$2,000
- CELLSEARCH$732
- NO PRODUCT DISCUSSED$407
- PYLARIFY$154
- Carto 3 System$123
How this compares
$8,619,932 in reported general payments places this provider in the 95th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 114 | $1,471,809 |
| CabometyxCabozantinib S-Malate | 26 | $572,343 |
| XtandiEnzalutamide | 41 | $493,050 |
| WeliregBelzutifan | 14 | $296,337 |
| InlytaAxitinib | 15 | $268,441 |
| OrgovyxRelugolix | 18 | $54,849 |
| Abiraterone Acetate | 140 | $51,199 |
| Prednisone | 158 | $718 |
| Bicalutamide | 21 | $276 |
| Dexamethasone | 19 | $240 |
| Prochlorperazine Maleate | 14 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerNubeqa | $56,890 | $1,471,809114 claims |
| Exelixis Inc.Cabometyx | $2,837 | $572,34326 claims |
| Astellas Pharma US IncXtandi | $11,810 | $493,05041 claims |
| MerckWelireg | $4,754,244 | $296,33714 claims |
| PfizerInlyta | $154,854 | $268,44115 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $2,342 | $54,84918 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $45 | $51,199140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 170 medical oncology providers in North Carolina.
Other medical oncology in Durham
- John StricklerDurham$23.5M
- Jeffrey ClarkeDurham$7.7M
- Neal ReadyDurham$6.7M
- Niharika MettuDurham$3.7M
- Michael HarrisonDurham$3.1M
- Thomas LeblancDurham$2.4M
- Brent HanksDurham$1.5M
- Jingquan JiaDurham$502K
- Sundhar RamalingamDurham$282K
- Jeffrey ShevachDurham$246K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.